Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC) [abstract 2587] - Robert,F.BG.; Dicke,J. (Proc Am Soc Clin Oncol, 2003)